Validation Requirements for Disinfection Efficacy - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Validation Requirements for Disinfection Efficacy


Pharmaceutical Technology
Volume 37, Issue 1, pp. 35

Q Is the periodic re-evaluation of disinfectant efficacy useful in any way? I have been asked to repeat these studies even though they have been done in the past. There's been no change to the materials or methods since that time.


John S. Kent
A In the pharmaceutical manufacturing industry, operating under GMPs, the periodic revalidation of disinfection efficacy is not scientifically justified or required provided the disinfectant used remains the same, the dilution of the disinfectant is still the same, the challenge organisms (including environmental isolates) are still the same, the manufacturing environment surfaces are still the same and the vendor for the disinfectant is still the same. To my knowledge, only when one of these five elements regarding cleanroom disinfection is changed are you required to repeat the validation of disinfection efficacy testing. Periodic revalidation of a disinfectant serves no useful scientific purpose and I do not know of an FDA regulation that states that one must periodically revalidate disinfectants. Be sure to execute the disinfection efficacy validation properly and have complete documentation.

John S. Kent, PhD
Principal, Pharmaceutical Development Consulting
San Mateo, CA (USA) 94403

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
18%
To all process for new products only
14%
To select process for new products only
23%
To select processes for both new and legacy products
20%
Do not use QbD
25%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here